Johnson & Johnson to buy Momenta for about $6.5 billion

(Reuters) – Johnson & Johnson (JNJ.N) said on Wednesday it would buy Momenta Pharmaceuticals Inc (MNTA.O) for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

J&J will pay $52.50 for each Momenta share, a 70.4% premium to Tuesday’s closing price.


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments